The cell and gene therapy (CGT) industry achieved a significant milestone at the end of 2022: the first approval of an allogeneic T-cell therapy in the world.
Inato has raised $20 million in early-stage financing to support the continued development of its clinical trial marketplace, which connects sponsors with its network of t